A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin

• Sponsor: Seagen Inc. (Industry)
• Overall Status: Completed
• CT.gov ID: NCT03826602
• Collaborator: (none)
• Enrollment: 18
• Location: 1
• Arm: 1
• Actual Duration (Months): 1
• Patients Per Site Per Month: 17.7

Study Details

Study Description

Brief Summary

This study is being done to look at how tucatinib might affect the way another drug (metformin) works. It will look at healthy volunteers and how tucatinib affects how the body absorbs metformin. This will help us find out whether tucatinib is safe to give together with metformin. The study will also look at how tucatinib affects how the kidneys work.

Condition or Disease	Intervention/Treatment	Phase
Drug-drug Interaction	Drug: Tucatinib; Drug: Metformin; Drug: Iohexol	Phase 1

Detailed Description

This is a single center, fixed-sequence, drug-drug interaction study to assess the effects of multiple oral doses of tucatinib on the pharmacokinetics of a single oral dose of metformin in healthy subjects. The primary objective of the study is to assess the effects of tucatinib on the single-dose PK of metformin. Secondary objectives of the study are to (1) assess the safety and tolerability of metformin when coadministered with tucatinib and (2) assess the effects of tucatinib on renal function using iohexol as glomerular filtration rate (GFR) marker.

Study Design

• Study Type: Interventional
• Actual Enrollment: 18 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Effects of Tucatinib of the Pharmacokinetics of Metformin in Healthy Male and Female Subjects
• Actual Study Start Date: Feb 12, 2019
• Actual Primary Completion Date: Mar 8, 2019
• Actual Study Completion Date: Mar 15, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Tucatinib plus metformin Tucatinib administered twice daily on Days 2-8. Metformin administered as a single dose on Days 1 and 8. Iohexol administered via IV push on Days 1 and 8	Drug: Tucatinib; 150mg administered orally twice daily; Drug: Metformin; 850mg administered orally; Drug: Iohexol; 1500 mg administered intravenously (IV)

Outcome Measures

Primary Outcome Measures

1. Maximum observed plasma concentration (Cmax) of metformin [Up to 9 days]

2. Time to maximum observed plasma concentration (tmax) of metformin [Up to 9 days]

3. Half-life (t1/2) of metformin [Up to 9 days]

4. Area under the plasma concentration-time curve from time 0 to the last available measurement (AUC0-last) of metformin [Up to 9 days]

5. Area under the plasma concentration time curve to time 0 extrapolated to infinity (AUC0-inf) of metformin [Up to 9 days]

6. Apparent volume of distribution (V2/F) of metformin [Up to 9 days]

7. Oral clearance (CL/F) of metformin [Up to 9 days]

Secondary Outcome Measures

1. Incidence of adverse events (as assessed by AE assessments, clinical laboratory tests, physical examinations, vital signs measurements, and 12-lead electrocardiogram) [Up to 16 days]

2. Glomerular Filtration Rate (GFR) as measured by iohexol plasma clearance [Up to 8 days]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Healthy status, as defined by the absence of evidence of any clinically significant findings

• Males must agree to use a barrier method of birth control and not donate sperm during study plus 30 days after last dose of study drug

• Weight of ≥60kg

• Body mass index between 18.0 and 32.0 kg/m² (inclusive)

• Ability to abstain from alcohol-, caffeine-, and xanthine-containing food and beverages from 48 hours prior to admission through study discharge

• All nonregular medication (including over-the-counter medication, health supplements, and herbal remedies) must be stopped at least 28 days prior to admission

Exclusion Criteria:

• Females who are of childbearing potential or lactating

• Males with female partners who are pregnant, lactating, or planning to become pregnant within 30 days of the study

• Use of any investigational drug or device within 30 days of study start

• Use of tobacco products within 21 days prior to admission

• Routine or chronic use of more than 3 grams of acetaminophen daily

• Strenuous activity, sunbathing, and contact sports within 72 hours prior to first admission and for the duration of the study

• Blood transfusion within 90 days of study drug administration

• History of alcoholism or drug abuse within 2 years

• History of alcohol consumption exceeding 7 drinks/week for female participants or 14 drinks/week for male subjects

• History of donation of more than 450 mL of blood within 60 days prior to dosing, or planned donation before 30 days have elapsed since intake of study drug

• Plasma or platelet donation within 7 days of initial study drug administration

• Positive screening test for Hepatitis B, Hepatitis C, or HIV 1 or 2 (human immunodeficiency virus)

• Acute or chronic metabolic acidosis, including diabetic ketoacidosis

• Renal disease or dysfunction as suggested by serum creatinine levels or abnormal creatinine clearance

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Pharmaceutical Research Associates	Salt Lake City	Utah	United States	84107

Sponsors and Collaborators

• Seagen Inc.

Investigators

• Study Director: JoAl Mayor, PharmD, BCOP, Seagen Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Seagen Inc.
• ClinicalTrials.gov Identifier: NCT03826602
• Other Study ID Numbers: SGNTUC-020
• First Posted: Feb 1, 2019
• Last Update Posted: Mar 27, 2019
• Last Verified: Mar 1, 2019

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Metformin; Tucatinib

Study Results

No Results Posted as of Mar 27, 2019